| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9155273 | American Heart Journal | 2005 | 7 Pages |
Abstract
In patients with NSTACS, enoxaparin significantly reduced the rates of recurrent ischemic events and therapeutic procedures in the short term, with sustained benefit at 6 m compared to tinzaparin.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Christos MD, Lampros K. MD, MRCP, FESC, Nikos MD, Kostas PhD, Katerina K. MD, PhD, Dimitris MD, John A. MD, FACC, Dimitris A. MD, FESC,